BRPI0819105A2 - composition for the treatment and prevention of eyelid edema - Google Patents

composition for the treatment and prevention of eyelid edema

Info

Publication number
BRPI0819105A2
BRPI0819105A2 BRPI0819105A BRPI0819105A BRPI0819105A2 BR PI0819105 A2 BRPI0819105 A2 BR PI0819105A2 BR PI0819105 A BRPI0819105 A BR PI0819105A BR PI0819105 A BRPI0819105 A BR PI0819105A BR PI0819105 A2 BRPI0819105 A2 BR PI0819105A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
composition
eyelid edema
eyelid
Prior art date
Application number
BRPI0819105A
Other languages
Portuguese (pt)
Inventor
Minno George
Jeffrey Lane Keith
Barry Abelson Mark
Jonathan Chapin Matthew
Original Assignee
Aciex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aciex Therapeutics Inc filed Critical Aciex Therapeutics Inc
Publication of BRPI0819105A2 publication Critical patent/BRPI0819105A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
BRPI0819105A 2007-11-08 2008-11-06 composition for the treatment and prevention of eyelid edema BRPI0819105A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US751107P 2007-11-08 2007-11-08
PCT/US2008/012513 WO2009061431A2 (en) 2007-11-08 2008-11-06 Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor

Publications (1)

Publication Number Publication Date
BRPI0819105A2 true BRPI0819105A2 (en) 2019-09-24

Family

ID=40329067

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819105A BRPI0819105A2 (en) 2007-11-08 2008-11-06 composition for the treatment and prevention of eyelid edema

Country Status (8)

Country Link
EP (1) EP2219630A2 (en)
JP (1) JP2011503061A (en)
CN (1) CN101977595A (en)
AU (1) AU2008325214A1 (en)
BR (1) BRPI0819105A2 (en)
CA (1) CA2705050A1 (en)
MX (1) MX2010005012A (en)
WO (1) WO2009061431A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US9173945B2 (en) * 2011-11-01 2015-11-03 Rohto Pharmaceutical Co., Ltd. Ophthalmological aqueous composition
EA021247B1 (en) * 2012-03-26 2015-05-29 Ооо "Фармацевтическая Компания "Славянская Аптека" Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)
EA021234B1 (en) * 2012-03-27 2015-05-29 Ооо "Фармацевтическая Компания "Славянская Аптека" Pharmaceutical composition having vasoconstricting, anticongestant, anti-inflammatory activity (embodiments)
JP6373551B2 (en) * 2012-05-30 2018-08-15 味の素株式会社 Gallotannin-containing composition
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
WO2014182610A2 (en) * 2013-05-06 2014-11-13 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
TWI705812B (en) 2014-12-01 2020-10-01 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
JP2019509330A (en) 2016-01-26 2019-04-04 レベーション ファーマ リミテッド Alpha adrenergic agonist composition and use
EP3970803A1 (en) * 2020-09-22 2022-03-23 Beiersdorf AG Cosmetic composition of low osmolality
WO2022187306A1 (en) * 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2618428A (en) * 1947-01-27 1952-11-18 John K M Harrison Shock resistant container
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
IT1248014B (en) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa PROTRACTED OPHTHALMIC PREPARATIONS
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US7691829B2 (en) * 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
JP2001187728A (en) * 1999-12-28 2001-07-10 Lion Corp Ophthalmic composition
DE10000612A1 (en) * 2000-01-10 2001-07-19 Min Becker Aqueous active substance preparations, especially eye drops, nasal drops and nasal sprays, contain sodium chloride in place of preservatives
JP2002308775A (en) * 2001-04-06 2002-10-23 Rohto Pharmaceut Co Ltd External composition
US7288263B2 (en) * 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
PT2377557T (en) * 2004-11-24 2017-02-07 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods of use thereof
JP2006232792A (en) * 2005-02-21 2006-09-07 Aile De Beaute:Kk Skin ageing-improving cosmetic
CN102895234A (en) * 2006-03-31 2013-01-30 维斯塔肯药品有限责任公司 Ocular allergy treatments
EP2015733A2 (en) * 2006-04-26 2009-01-21 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling

Also Published As

Publication number Publication date
CA2705050A1 (en) 2009-05-14
CN101977595A (en) 2011-02-16
AU2008325214A1 (en) 2009-05-14
EP2219630A2 (en) 2010-08-25
MX2010005012A (en) 2010-06-23
JP2011503061A (en) 2011-01-27
WO2009061431A2 (en) 2009-05-14
WO2009061431A3 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
BRPI0819105A2 (en) composition for the treatment and prevention of eyelid edema
BRPI0819241A2 (en) Amine-derived compounds for the treatment of ophthalmic disorders and diseases
CR11019A (en) 3-IMIDAZOLIL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
BRPI0916862A2 (en) compounds useful for the treatment of degenerative and inflammatory diseases
BRPI0921237A2 (en) methods and compositions for the treatment of complement-associated disorders
ES2525801T8 (en) Compositions and methods for the prevention and treatment of autoimmune diseases
BRPI0919920A2 (en) compounds for treating ophthalmic diseases and disorders
BRPI0716844A2 (en) Useful Kinase Inactors for the Treatment of Proliferative Diseases
BRPI0818799A2 (en) Compositions for the treatment of parkinson's disease
BRPI0921321A2 (en) methods for the treatment of tumors and tumors
BRPI0915282A2 (en) gip-based mixed agonists for the treatment of metabolic disorders and obesity
BRPI0813725A2 (en) METHODS AND COMPOSITIONS FOR DISEASE TREATMENT
BRPI1015569A2 (en) compounds useful for the treatment of degenerative and inflammatory diseases.
BRPI0917444A2 (en) gastric retention pharmaceutical compositions for the treatment and prevention of snc diseases
DK2474321T3 (en) Compositions for the treatment of collagen-mediated diseases
BRPI0816712A2 (en) interval therapy for the treatment of tinnitus
BRPI1007929A2 (en) "methods and compositions for treating neovascularization".
BRPI0911612A2 (en) compositions and methods for the treatment of multiple sclerosis.
BRPI0915439A2 (en) topical composition for the treatment of actinic keratosis
BRPI0917440A2 (en) ophthalmic pharmaceutical compositions for the treatment of neoangiogenic eye disorders
BRPI0923567A2 (en) new antibacterial agents for the treatment of gram positive infections
DK2117565T3 (en) APPLICATION OF CHITOSANES FOR THE TREATMENT OF NON-FLAMMATORY DISEASES
GB0909297D0 (en) Composition for the treatment of skin conditions
BRPI0914454A2 (en) "composition for the treatment of epithelial tissue"
BRPI0810207A2 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.